flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk ๐จ Journal Club: FLOW Trial โ FLOW clinical Trial (funded by
Pay in 4 interest-free payments of $6.56 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Sep 4 - Sep 9


















